Status:
TERMINATED
Effects of PDE-5 Inhibition on Postprandial Hyperglycemia in Type 2 Diabetes
Lead Sponsor:
Vastra Gotaland Region
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
40-65 years
Phase:
PHASE1
Brief Summary
An increase of blood flow and capillary permeability decrease the impact of an endothelial barrier for glucose and insulin allowing them to reach their target cells in peripheral insulin sensitive org...
Detailed Description
An increase of blood flow and capillary permeability decrease the impact of an endothelial barrier for glucose and insulin allowing them to reach their target cells in peripheral insulin sensitive org...
Eligibility Criteria
Inclusion
- Postmenopausal state, defines as natural amenorrhea for at least 12 months.
- Age; females 52-65 years, males: 40-65 years.
- Type 2 diabetes based on fasting plasma glucose or 2-hr glucose after an OGTT.
- Diabetes duration less than 5 years.
Exclusion
- Patients with concurrent use of nitrates or NO donors, history of heart or cerebrovascular disease, cardiac failure (stages NYHA II-IV), uncontrolled hypertension (\> 160/100 mm Hg), significant diabetic complications, and inadequate glycemic control (HbA1c \> 7%, ref value 3.5-5.3%)
- Patients on glitazones, insulin, beta-blockers, ACE-inhibitors and corticosteroids
Key Trial Info
Start Date :
November 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2011
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT01238224
Start Date
November 1 2009
End Date
November 1 2011
Last Update
February 12 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Wallenberg Laboratory, Dept of Molecular and Clinical Medicine, Sahlgrenska University Hospital, Bruna stråket 16,
Gothenburg, Sweden, SE 413 45